Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CASR | P41180 | 3/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.31 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.31 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | BCR | P11274 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6869734 | 0.89 | CASR (0.35) | SCN9AMAPTCASRNOTUMP2RX7 | |
| SCHEMBL6872107 | 0.85 | PDE2A (0.38) | SCN9AMAPTPDE2AMKNK2ABL1 | |
| SCHEMBL2053281 | 0.80 | PDE2A (0.38) | SCN9AMAPTPDE2AMKNK2ABL1 | |
| SCHEMBL6871074 | 0.77 | MEN1 (0.36) | CASRP2RX7 | |
| SCHEMBL12543430 | 0.75 | SCN9A (0.38) | SCN9AMAPTCASRMKNK2KDM4E | |
| SCHEMBL2033959 | 0.73 | P2RX7 (0.42) | P2RX7 | |
| SCHEMBL6869518 | 0.73 | P2RX7 (0.42) | P2RX7 | |
| SCHEMBL6870112 | 0.73 | P2RX7 (0.41) | P2RX7 | |
| SCHEMBL6871327 | 0.73 | P2RX7 (0.41) | P2RX7 | |
| SCHEMBL12643105 | 0.70 | CNR2 (0.44) | MAPTP2RX7CNR2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480232-B1 | DISUBSTITUTED ]4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1H-INDOL-3-YL]-METHANONES | SANOFI SA (FR) | 2013-10-02 | — | — | EP | disclosed |
| EP-2480232-B1 | DISUBSTITUTED ]4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1H-INDOL-3-YL]-METHANONES | SANOFI SA (FR) | 2013-10-02 | — | — | EP | disclosed |
| US-20120142735-A1 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]- 1H-INDOL-3-YL]-METHANONES | SANOFI (FR) | 2012-06-07 | — | — | US | disclosed |
| US-20120142735-A1 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]- 1H-INDOL-3-YL]-METHANONES | SANOFI (FR) | 2012-06-07 | — | — | US | disclosed |
| US-20120142735-A1 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]- 1H-INDOL-3-YL]-METHANONES | SANOFI (FR) | 2012-06-07 | — | — | US | disclosed |
| WO-2011022449-A1 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1H-INDOL-3-YL]-METHANONES | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142735-A1 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]- 1H-INDOL-3-YL]-METHANONES | CMA1, TPSB2, TPSAB1 | SCN9A 1716/4885MAPT 2417/4885CASR 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.